Pamela Sung

MD, PhD
Hematologic Oncology

Cancers Treated:

Specializing In:

Targeted therapy Molecular Diagnostics Translational Medicine

Research Interests:

FLT3 mutated AML Therapeutic Resistance Epigenetics

About Pamela Sung

Biography:

I joined the faculty at Roswell Park in July 2021 with a dual appointment in the Department of Medicine and Department of Pharmacology & Therapeutics. I am a physician-scientist in the field of leukemia biology. I completed my MD/PhD at New York University and my clinical and post-doctoral training at the Hospital of the University of Pennsylvania. I treat patients with bone marrow cancers (AML, ALL, CML, MDS, and MPNs) and non-malignant blood disorders.  My laboratory focuses on FLT3 mutated AML and improving responses to targeted therapy.

Positions

Roswell Park Comprehensive Cancer Center

  • Assistant Professor of Oncology
  • Department of Medicine - Leukemia
  • Department of Pharmacology & Therapeutics

Background

Education and Training:

  • 2012 - MD - Medicine, New York University School of Medicine, New York, NY
  • 2010 - PhD - Cell and Molecular Biology, New York University, New York, NY
  • 2004 - BA - Biology and Chemistry, Cornell University, Ithaca, NY

Residency:

  • 2012-2014 - Internal Medicine Research Pathway, Hospital of the University of Pennsylvania, Philadelphia, PA

Fellowship:

  • 2014-2018 - Hematology/Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA

Board Certification:

  • Internal Medicine
  • Medical Oncology
  • Hematology

Professional Memberships:

  • American Society of Hematology
  • American Association for Cancer Research

Professional Experience:

  • 2019-2021 - Instructor of Medicine, University of Pennsylvania, Philadelphia, PA
  • 2018-2019 - Measey Physician Scientist-Fellow, University of Pennsylvania, Philadelphia, PA

Honors & Awards:

  • 2019 - Special Fellow Award, Leukemia and Lymphoma Society
  • 2017 - Research Training Award for Fellows, American Society of Hematology
  • 2017 - Future Leaders Award for Clinical Research in Hematology, Celgene Corporation

Publications

Full Publications list on PubMed

Sung PJ, Sugita M, Koblish H, Perl AE, Carroll M. Hematopoietic cytokines mediate resistance to targeted therapy in FLT3-ITD acute myeloid leukemia. Blood Advances. 2019 Apr 9;3(7):1061-1072. PubMed PMID: 30944098.

Sung PJ and Luger SM. Minimal residual disease in acute myeloid leukemia. Curr. Treat. Options in Oncol. 2017 Jan;18(1):1-14. PubMed PMID: 28110381.

Manur R, Sung PJ, Loren AW, Ritchie EK, Frank D, Bagg A, Geyer JT, Bogusz AM. Leukemia lineage switch in a t(8;22)(p11.2;q11.2)/BCR-FGFR1-rearranged myeloid/lymphoid neoplasm with RUNX1 mutation – diagnostic pitfalls and clinical management including FGFR1 inhibitor pemigatinib. Leukemia & Lymphoma. 2020 Feb; 61(2):450-454. PubMed PMID: 31524018.

Sung PJ, Tsai FD, Vais H, Court H, Yang J, Fehrenbacher N, Foskett JK, Philips MR. Phosphorylated K-Ras limits cell survival by blocking Bcl-xL sensitization of inositol trisphosphate receptors. Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):20593-8. PubMed PMID: 24297914; PubMed Central PMCID: PMC3870738.

Sung PJ, Rodrigues AB, Kleinberger A, Quatela S, Bach EA, Philips MR. Cytosolic Ras supports eye development in Drosophila. Mol Cell Biol. 2010 Dec;30(24):5649-57. PubMed PMID: 20937772; PubMed Central PMCID: PMC3004281.